Drugs & Targets FDA approves epcoritamab-bysp for follicular lymphoma indications November 21, 2025Vol.51 No.43
Drugs & Targets EC approves Libtayo as adjuvant treatment of high-risk cutaneous squamous cell carcinoma November 21, 2025Vol.51 No.43
Drugs & Targets GSK and LTZ collaborate to advance novel myeloid cell engagers in oncology November 21, 2025Vol.51 No.43
Drugs & Targets Freenome and Roche to expand collaboration to develop and commercialize cancer screening tests outside the U.S. November 21, 2025Vol.51 No.43
Drugs & Targets Microsoft and Qure.ai collaborate to accelerate AI lung cancer detection November 21, 2025Vol.51 No.43
Conversation with The Cancer LetterRegulatory News Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director November 14, 2025Vol.51 No.42By Paul Goldberg
Regulatory News FDA to remove black box warnings on hormone therapy for menopauseTrump-era “gold standard science” is not to be confused with gold standard of scientific evidence November 14, 2025Vol.51 No.42By Claire Marie Porter
Trials & Tribulations Smoldering multiple myeloma: Rethinking the waiting game November 14, 2025Vol.51 No.42By C. Ola Landgren
